Phoenix Equity Partners
UK private equity firm
From Wikipedia, the free encyclopedia
Phoenix Equity Partners is a United Kingdom mid-market private equity firm. It specialises in partnering with founder-entrepreneurs and their teams to grow their businesses.[1] Phoenix typically invests £10–60 million of equity per partnership.[2]
| Company type | Limited partnership |
|---|---|
| Industry | Private equity |
| Founded | 2001 |
| Headquarters | London, United Kingdom |
Key people | David Burns (Managing Partner), Kevin Keck (Managing Partner) |
| Products | private equity funds |
| Total assets | £900 million |
| Website | www.phoenix-equity.com |
History
Phoenix was co-founded in 2001 by Hugh Lenon, Sandy Muirhead, James Thomas, David Burns and Kevin Keck. [3] David Burns and Richard Daw were made Managing Partners in 2014.[4]
More recently, in September 2024, the firm launched its Flagship Fund and Growth Partnership Fund, raising over £600 million to pursue mid-market buyouts and growth investments across the UK and Europe. [5]
In 2025, Kevin Keck was appointed co-Managing Partner alongside David Burns, reflecting a leadership update at the firm. [6]
Recent transactions
Phoenix has been active across technology, healthcare, and mid-market buyouts, with a series of investments and fund launches that reflect its sector-focused strategy.
In August 2024, Phoenix backed Cybanetix, a UK-based cybersecurity provider specialising in managed detection and response for mid-market businesses. [7]
The following month, the firm closed a £200 million continuation vehicle for Nineteen Group and Envisage Dental, extending ownership to fund buy-and-build strategies and organic growth initiatives. [8]
In December 2024, Phoenix acquired a stake in London Gynaecology, a specialist women's health clinic group. [9] The deal provided capital to expand services and locations amid rising investor interest in women's health. [10]
In July 2025, Phoenix invested in FutureMeds, a clinical trial management services provider operating across Europe, supporting growth in patient recruitment and site capacity across its network. [11]
